0.395

3.67% 0.014

Allurion Technologies Inc (ALUR)

Overview News Price History Option Chain Discussions Forecast

Allurion Technologies Inc stock is traded at $0.395, with a volume of 218.79K. It is up +3.67% in the last 24 hours and down -48.03% over the past month. Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Previous Close:

$0.381

Open:

$0.41

24h Volume:

218.79K

Relative Volume:

0.85

Market Cap:

$24.76M

Revenue:

$64.42M

Net Income/Loss:

$-73.78M

P/E Ratio:

EPS:

Net Cash Flow:

$-60.50M

1W Performance:

-13.72%

1M Performance:

-48.03%

6M Performance:

-75.77%

1Y Performance:

-90.25%

1-Day Range:

$0.3624

$0.415

1-Week Range:

$0.3624

$0.5699

52-Week Range:

$0.31

$4.15

Allurion Technologies Inc Stock (ALUR) Company Profile

Name

Allurion Technologies Inc

Sector

Healthcare (1200)

Industry

Medical Devices (153)

Phone

508-647-4000

Address

11 HURON DR STE 200, NATICK

Employee

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

ALUR's Discussions on Twitter

Compare ALUR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALUR Allurion Technologies Inc	0.395	24.76M	64.42M	-73.78M	-60.50M	0.00
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-02-24	Initiated	TD Cowen	Buy
Sep-06-24	Initiated	ROTH MKM	Buy
Feb-09-24	Initiated	Jefferies	Buy

Allurion Technologies Inc Stock (ALUR) Latest News

Nov 26, 2024

Allurion launches AI weight loss support GLP-1 drug programme - Yahoo! Voices

Nov 26, 2024

Nov 25, 2024

Allurion launches compounded GLP-1 program as FDA aims to end access - Yahoo Finance

Nov 25, 2024

Allurion launches compounded GLP-1 program as FDA aims to ends access - Yahoo Finance

Nov 25, 2024

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program - The Bakersfield Californian

Nov 25, 2024

Nov 18, 2024

Allurion Technologies (NYSE:ALUR) Cut to Neutral at Chardan Capital - Defense World

Nov 18, 2024

Nov 16, 2024

Earnings Release: Here's Why Analysts Cut Their Allurion Technologies Inc. (NYSE:ALUR) Price Target To US$1.83 - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Take Care Before Jumping Onto Allurion Technologies Inc. (NYSE:ALUR) Even Though It's 42% Cheaper - Simply Wall St

Nov 15, 2024

Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Allur - GuruFocus.com

Nov 15, 2024

Allurion Technologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 15, 2024

Citadel Advisors LLC Acquires New Stake in Allurion Technologies Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

TD Cowen maintains buy rating for Allurion Technologies at $2.00 target - Investing.com UK

Nov 14, 2024

Earnings call: Allurion Technologies outlines strategy amid Q3 challenges - Investing.com

Nov 14, 2024

Earnings call: Allurion Technologies outlines strategy amid Q3 challenges By Investing.com - Investing.com Australia

Nov 14, 2024

Chardan Capital Downgrades Allurion Technologies (ALUR) - MSN

Nov 14, 2024